MONTREAL, May 8, 2019 /CNW/ - Mondias Naturals
Inc. ("Mondias" or the "Company") (TSXV: NHP) is pleased to
announce the appointment of Mr. André Rancourt as Executive
Chairman, and of Mr. Derek Lindsay
as Vice President, Corporate Development, effective immediately.
Mr. Rancourt was previously Chairman of the Board.
"The appointment of Mr. Rancourt as Executive Chairman clearly
strengthens the structure and depth of our management," said
Jean-Philippe Gravel, Chief
Executive Officer of Mondias. "Mr. Rancourt's wealth of expertise,
vast network and involvement in day-to-day strategy and operations
will greatly contribute to our expansion efforts."
"We are also pleased to have Mr. Lindsay join the Mondias team.
His proven expertise in raising equity and financing projects,
structuring creative strategic partnerships, increasing investor
awareness and completing acquisitions will be an asset for Mondias
as the Company embarks on its next growth phase," added Mr.
Gravel.
Mr. Lindsay is a seasoned financial executive with extensive
international experience in accelerating the growth of emerging
companies. Over the course of his career, he has been instrumental
in raising significant equity and debt financing, completing
acquisitions and closing strategic partnerships. Mr. Lindsay holds
an M.B.A. from the Tuck School of Business at Dartmouth College and a B.A. from Middlebury College, U.S.A.
Mr. Lindsay's responsibilities with Mondias include financing,
investor relations and acquisition activities, as well as
participating in the identification and assessment of new business
opportunities, with the goal of accelerating the Company's
growth.
The Company also announces that the board of directors has
approved the granting of 650,000 stock options to directors,
officers, consultants and employees under the Company's stock
option plan. The exercise price of the options is $0.235 (the closing price of the shares on
May 6, 2019). The options will vest
in equal instalments over a three-year period and expire on
May 6, 2029. The options and
the stock option plan are subject to shareholder approval at
Mondias' annual and special shareholder meeting on June 10, 2019.
Pursuant to this stock option grant, the Company has a total of
3,600,408 stock options outstanding, which represents less than 6%
of the Company's issued and outstanding common shares.
About Mondias Natural Products Inc.
Mondias
specializes in the commercialization and development of
evidence-based botanical products for the health care,
bio-agriculture and organic markets. The company sells both oral
and topical botanical agents to help manage unmet medical needs
through its Holizen Laboratories division. Mondias is also
developing botanical-based specialty fertilizers for use on
household plants, lawns and golf courses and in urban gardens,
nurseries and greenhouses, in collaboration with McGill's Faculty
of Agricultural and Environmental Sciences.
For more information, visit: mondias.ca
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Forward-looking statements
Some statements in this
release may contain forward-looking information. All statements,
other than of historical fact, that address activities, events or
developments that the Company believes, expects or anticipates will
or may occur in the future (including, without limitation,
statements regarding potential acquisitions and financings) are
forward-looking statements. Forward-looking statements are
generally identifiable by use of the words "may", "will", "should",
"continue", "expect", "anticipate", "estimate", "believe",
"intend", "plan" or "project" or the negative of these words or
other variations on these words or comparable terminology.
Forward-looking statements are subject to a number of risks and
uncertainties, many of which are beyond the Company's ability to
control or predict, that may cause the actual results of the
Company to differ materially from those discussed in the
forward-looking statements. Factors that could cause actual results
or events to differ materially from current expectations include,
among other things, without limitation, the inability of the
Company to obtain sufficient financing to execute the Company's
business plan; competition; regulation and anticipated and
unanticipated costs and delays, the success of the Company's
research and development strategies, the success of this joint
venture, the ability to obtain orphan drug status, the
applicability of the discoveries made therein, the successful and
timely completion and uncertainties related to the regulatory
process, the timing of clinical trials, the timing and outcomes of
regulatory or intellectual property decisions and other risks
disclosed in the Company's public disclosure record on file with
the relevant securities regulatory authorities. Although the
Company has attempted to identify important factors that could
cause actual results or events to differ materially from those
described in forward-looking statements, there may be other factors
that cause results or events not to be as anticipated, estimated or
intended. Readers should not place undue reliance on
forward-looking statements. While no definitive documentation has
yet been signed by the parties and there is no certainty that such
documentation will be signed. The forward-looking statements
included in this news release are made as of the date of this news
release and the Company does not undertake an obligation to
publicly update such forward-looking statements to reflect new
information, subsequent events or otherwise unless required by
applicable securities legislation.
SOURCE Mondias Natural Products Inc.